Previously unpublished trial data explain effects and side effects of key MS drug
Tuesday, June 13, 2017 - 10:32
in Health & Medicine
Alemtuzumab is a highly effective drug for multiple sclerosis, approved in more than 60 countries and used by more than 12,000 patients worldwide. However, there is an almost 50 per cent risk of secondary autoimmune diseases, some of which are life-threatening, such as platelet and kidney diseases.